抗肿瘤血管生成联合介入治疗中晚期肝癌的临床观察

The clinical efficacy of anti-angiogenesis therapy combined with interventional chemotherapy on middle and terminalliver cancer patients

目的探讨抗肿瘤血管生成联合介入治疗中晚期肝癌的临床疗效。方法选取2009年5月～2012年5月我院收治139例中晚期肝癌患者的临床资料进行回顾性分析,按照随机数字表法将其分为观察组72例(抗肿瘤血管生成联合介入化疗)和对照组(仅接受介入化疗)67例,对两组患者的临床疗效和Kamofsky评分进行比较分析。结果 (1)观察组的CR+PR率为43.1%明显高于对照组28.4%,两组比较差异有统计学意义(P<0.05);(2)两组患者在Kamofsky评分比较,观察组的Kamofsky评分明显高于对照组,差异有统计学意义(P<0.05)。结论抗肿瘤血管生成联合介入治疗中晚期肝癌能有效改善患者生活质量,延长患者生存时间,为治疗肝癌非手术的首选方法。

Objective To explore the clinical efficacy of anti-angiogenesis therapy combined with interventional treatment on middle and terminal liver cancer patients.Methods A retrospective analysis of 139 cases patients with middle and terminal liver cancer from May 2009 to May 2012 in our hospital were divided into observation group （ 72 cases ） and control group （ 67 cases ）. Observation group was treated with anti-tumor angiogenesis therapy combined with interventional chemotherapy and Control group was treated with only interventional chemotherapy. The clinical curative effect and Kamofsky score were observed and compared in both groups. Results （ 1 ）The rate of CR ＂4- PR in observation group was obviously higher than that in control group there was significant difference（P 〈 0.05） ; （ 2 ） After treatment, Kamofsky score in observation group was higher than that in control group, with significant difference （P 〈 0.05）. Conclusion The effect of anti-angiogenesis therapy combined with interventional treatment on middle and terminal liver cancer patients is better, is worthy of clinical application.